Rheoxtech

Rheoxtech is transforming acute myocardial infarction care with the our reperfusion System — a first-in-class, catheter-based therapy that controls gradual reoxygenation at the precise moment of reflow to prevent reperfusion injury. Our mission is simple: preserve hearts, preserve lives. Why it matters: sudden reoxygenation when blocked coronary arteries are opened (reperfusion) can cause substantial, preventable cardiac damage — driving larger infarcts, heart failure, readmissions, and early mortality. Rheox™ is designed to intervene at that vulnerable moment without changing the established door-to-balloon workflow clinicians rely on. Evidence-driven: a retrospective clinical cohort using gradual reoxygenation observed markedly improved outcomes (clinical cohort observed an 87% lower mortality rate vs historical controls). Our translational PCI study confirmed prototype performance, demonstrating ~41% smaller infarct size and ~10× lower troponin release in an animal model. This data guided our design, clinical strategy, and regulatory engagement. Product highlights: Catheter + pump/cartridge platform that isolates target coronary flow and delivers a controlled venous/arterial blood mix. Designed for rapid deployment in high-risk STEMI and cardiogenic shock cases without delaying revascularization. Commercial & regulatory posture: Rheoxtech holds issued patents and multiple strong provisional filings protecting the platform. We recently met with the FDA and plan to pursue Breakthrough Device designation and an early feasibility study to accelerate clinical development. Team & approach: clinical leadership from experienced cardiac surgeons and interventional cardiologists, and serial med-tech operators with successful exits, anchor our strategy — combining surgical preservation science with pragmatic cath-lab workflows. If you're a clinician, partner, or investor interested in improving outcomes for high-risk AMI patients, contact us to learn more.

• Employees 2
• Founded 2022